Bcr-Abl gene mutation detection liquid-phase chip

Abstract

The invention discloses a Bcr-Abl gene mutation detection liquid-phase chip, which comprises a wild-type specific ASPE primer and a mutant specific ASPE primer respectively designed for each mutational site, microballoons respectively covered with a specific anti-tag sequence and primers used for amplifying a target sequence carrying mutational sites of M244V, L248V, D276G, G250E, Y253F / H, E255K / V, T315I, F317L, E355G, F359V, V379I, H396P / R and / or F486S on Bcr-Abl gene. The Bcr-Abl gene mutation detection liquid-phase chip has extreme good signal-noise ratio, and cross reaction is basically unavailable between a designed probe and the anti-tag sequence. The designed ASPE primer has extreme good specificity and can exactly distinguish the each type of mutational sites. The detecting methodis convenient in operation and can detect 16 types of mutational sites at one time while avoiding various uncertain factors existed in many operation processes, thereby being capable of greatly heightening the detecting accuracy rate.

Description

technical field [0001] The invention belongs to the field of molecular biology, relates to medicine and biotechnology, in particular to a Bcr-Abl gene mutation detection liquid phase chip. Background technique [0002] The Bcr-Abl fusion gene is a fusion gene formed by translocation between the Abl proto-oncogene on chromosome 9 and the Bcr gene on chromosome 22 in human cells. This gene produces a new mRNA, the encoded protein is P210, and P210 can cause continuous activation of protein kinase, causing excessive proliferation of white blood cells and chronic myeloid leukemia (CML). Tyrosine kinase plays a key role in the occurrence of CML, and inhibiting its active components has become a new approach for CML treatment. The first-line drug imatinib for the treatment of CML is a specific Abl tyrosine kinase inhibitor, which can selectively bind to the Bcr-Abl receptor, preventing the transfer of phosphate groups from adenosine triphosphate to protein substrates, making it ...

AI Technical Summary

Problems solved by technology

[0004] At present, the detection products of Bcr-Abl are generally based on PCR technology, such as fluorescent quantitative PCR method, FRET method and DNA sequencing method, which have the disadvantages of easy sample contamination, high false positive rate, and low sensitivity. At the same time, due to the limitation of detection throughput , cannot meet the needs of practical applications

Images